Company intelligence / Profile preview

111

Ownership: Public · YI
Development stage: Commercial

Overview

Achieved first-ever annual operating profit in fiscal year 2024 with income from operations of RMB2.1 million (~US$0.3 million) and positive operating cash flow of RMB263.0 million (~US$36 million). The business has demonstrated resilience amid challenging macroeconomic conditions by leveraging its tech-enabled omni-channel healthcare platform.

Industry: Non-Academic Healthcare

Partnerships

Eli Lilly and Company (“Lilly”)Beilin Pharmaceutical Co.

Financials

Market cap: $28M
Total revenue: $2.4B
Enterprise value: $16M

Beyond the preview

Go deeper on 111.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 111.

Explore the full profile